These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 27068338)

  • 41. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. KRAS
    Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
    Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells.
    Caiola E; Salles D; Frapolli R; Lupi M; Rotella G; Ronchi A; Garassino MC; Mattschas N; Colavecchio S; Broggini M; Wiesmüller L; Marabese M
    Oncotarget; 2015 Oct; 6(30):30072-87. PubMed ID: 26353932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 48. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
    Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
    Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
    [No Abstract]   [Full Text] [Related]  

  • 50. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
    Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
    Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.
    Niemantsverdriet M; Schuuring E; Elst AT; van der Wekken AJ; van Kempen LC; van den Berg A; Groen HJM
    J Thorac Oncol; 2018 Dec; 13(12):e249-e251. PubMed ID: 30467046
    [No Abstract]   [Full Text] [Related]  

  • 53. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with
    Drilon A; Schoenfeld AJ; Arbour KC; Litvak A; Ni A; Montecalvo J; Yu HA; Panora E; Ahn L; Kennedy M; Haughney-Siller A; Miller V; Ginsberg M; Ladanyi M; Arcila M; Rekhtman N; Kris MG; Riely GJ
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936194
    [No Abstract]   [Full Text] [Related]  

  • 54. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
    Sato K; Akamatsu H; Koh Y; Ogawa K; Isa SI; Ando M; Tamiya A; Kubo A; Kitagawa C; Kawaguchi T; Yamamoto N
    BMC Cancer; 2022 Nov; 22(1):1148. PubMed ID: 36348317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.
    Abdel-Rahman O
    Ther Adv Respir Dis; 2016 Jun; 10(3):265-74. PubMed ID: 26893312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
    Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
    Judd J; Abdel Karim N; Khan H; Naqash AR; Baca Y; Xiu J; VanderWalde AM; Mamdani H; Raez LE; Nagasaka M; Pai SG; Socinski MA; Nieva JJ; Kim C; Wozniak AJ; Ikpeazu C; de Lima Lopes G; Spira AI; Korn WM; Kim ES; Liu SV; Borghaei H
    Mol Cancer Ther; 2021 Dec; 20(12):2577-2584. PubMed ID: 34518295
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.